The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice-Reference-Cited by-同舟云学术

The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice

Published:2020-09-01 Issue:7 Volume:36 Page:529-533
ISSN:1080-7683
Container-title:Journal of Ocular Pharmacology and Therapeutics
language:en
Short-container-title:Journal of Ocular Pharmacology and Therapeutics

Author:

Esaki Yoshihiko¹,Katsuta Osamu¹,Kamio Hitomi¹,Noto Takahisa¹,Mano Hidetoshi¹,Iwamura Ryo²,Yoneda Kenji²,Odani-Kawabata Noriko³⁴,Morishima Kenji¹,Shams Naveed K.⁴

Affiliation:

1. Santen Pharmaceutical Co., Ltd., Research and Development Division, Nara, Japan.

2. Ube Industries, Ltd., Pharmaceuticals Research Laboratory, Pharmaceutical Division, Yamaguchi, Japan.

3. Santen Pharmaceutical Co., Ltd., Osaka, Japan.

4. Santen, Inc., Research and Development Division, Emeryville, California, USA.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmacology,Ophthalmology

Link

https://www.liebertpub.com/doi/pdf/10.1089/jop.2020.0003

Reference24 articles.

1. Neuroprotective agents in the management of glaucoma

2. The Pathophysiology and Treatment of Glaucoma

3. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and optionsSupported by the EGS Foundation

4. Glaucoma

5. Meta-analysis of 24-Hour Intraocular Pressure Studies Evaluating the Efficacy of Glaucoma Medicines

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial;Clinical Ophthalmology;2024-07

2. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug;Current Opinion in Pharmacology;2024-02

3. Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients;Pharmaceuticals;2023-05-26

4. Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma;Journal of Ocular Pharmacology and Therapeutics;2023-02-01

5. Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells;PLOS ONE;2023-01-11